VCYT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Veracyte Inc (VCYT) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown impressive financial growth in its latest quarter and has positive analyst sentiment, the lack of recent trading signals, neutral technical indicators, and the absence of significant catalysts suggest that this is not an optimal entry point. The stock's pre-market price is slightly down, and its short-term trend indicates potential downside. It is advisable to monitor the stock for a better entry point or stronger signals.
The MACD is positive but contracting, RSI is neutral at 53.34, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot point of 32.771, with resistance at 34.54 and support at 31.003. Short-term trend analysis suggests a 60% chance of a slight decline in the next day, week, and month.
Strong financial performance in Q4 2025 with 18.55% YoY revenue growth, 704.79% YoY net income growth, and 733.33% YoY EPS growth. Analysts from Jefferies and Guggenheim maintain a Buy rating with a price target of $45, citing profitability, pipeline strength, and valuation.
Morgan Stanley downgraded the price target to $37 and maintains an Underweight rating. No significant hedge fund or insider trading activity. Lack of recent news or event-driven catalysts. Short-term trend analysis suggests potential downside.
In Q4 2025, Veracyte reported revenue of $140.64M (up 18.55% YoY), net income of $41.15M (up 704.79% YoY), EPS of $0.5 (up 733.33% YoY), and a gross margin of 72.07% (up 9.68% YoY).
Analysts are generally positive, with Jefferies and Guggenheim assigning Buy ratings and a $45 price target, citing strong fundamentals and growth potential. However, Morgan Stanley has an Underweight rating with a $37 price target, reflecting a more cautious outlook.
